• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innocan Pharma Corp (CSE: INNO )

    0.2500 UNCHANGED
    Streaming Delayed Price Updated: 3:25 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.2500
    Bid (Size) 0.2450 (40,000)
    Ask (Size) 0.2500 (20,000)
    Prev. Close 0.2500
    Today's Range 0.2500 - 0.2500
    52wk Range 0.2100 - 0.5200
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
    Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
    Via Benzinga
    This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
    Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -19.35%
    -19.35%
    1 Month
    +2.04%
    +2.04%
    3 Month
    -10.71%
    -10.71%
    6 Month
    -18.03%
    -18.03%
    1 Year
    +11.11%
    +11.11%

    More News

    Read More
    534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
    Via Benzinga
    CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
    Via Benzinga
    Exposures Product Safety
    Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis Product Safety
    CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
    Via Benzinga
    Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
    Via Benzinga
    Industry Update: Innocan Pharma Accelerates Commercialization in Europe Following Impressive Revenue Growth
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Innovative Delivery Systems Create Unique Opportunities in the Billion-Dollar Pain Market (CSE: INNO)
    Via AB Newswire
    Topics Cannabis
    Exposures Cannabis
    Innocan Pharma Provides an Operational Update
    Via Newsfile
    Topics Intellectual Property
    Exposures Intellectual Property
    Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
    Via Newsfile
    Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
    Via Newsfile
    Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
    Via Newsfile
    Topics Supply Chain
    Exposures COVID-19 Supply Chain
    Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
    Via Newsfile
    Topics Supply Chain
    Exposures COVID-19 Supply Chain
    Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada
    Via Newsfile
    Topics Supply Chain
    Exposures COVID-19 Supply Chain
    Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
    Via Newsfile
    Topics Artificial Intelligence Supply Chain
    Exposures Artificial Intelligence COVID-19 Supply Chain
    Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
    Via Newsfile
    Topics Economy Supply Chain
    Exposures COVID-19 Economy Supply Chain
    Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study
    Via Newsfile
    Topics Supply Chain
    Exposures COVID-19 Supply Chain
    Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
    Via Newsfile
    Topics Supply Chain
    Exposures COVID-19 Supply Chain
    Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
    Via Newsfile
    Topics Intellectual Property Supply Chain
    Exposures COVID-19 Intellectual Property Supply Chain
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.